Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Supernus makes and sells prescription medicines that treat brain and nervous system conditions like epilepsy, ADHD, Parkinson's disease, migraine, and opioid addiction.
Supernus Pharmaceuticals is a specialty drugmaker focused on the brain and nervous system. It sells prescription medicines that help people with epilepsy, ADHD, Parkinson's disease, migraine, and opioid use disorder. These are conditions that often need daily, long-term treatment, which means patients refill their prescriptions month after month.

Its best-known products include Trokendi XR and Oxtellar XR for epilepsy, Qelbree for ADHD, and Onapgo, a recently approved infusion therapy for Parkinson's disease. The company also sells Zurnai, an auto-injector for opioid overdose reversal, and has a long-acting injectable for opioid use disorder. Doctors prescribe these medicines, insurers and patients pay for them, and Supernus keeps the difference between what it costs to make the drug and what it can charge. The business runs on patents and exclusivity. A new drug gets years of protection from generic competition, and during that window Supernus can earn healthy margins. The risk is what happens when those windows close: cheaper generics arrive, prices fall, and revenue can drop fast. That is why the company spends heavily on developing and acquiring new treatments to replace the old ones before they lose protection.
Supernus is based in Rockville, Maryland, and its shares trade on Nasdaq. It is a mid-sized player in a field crowded with much larger competitors, so it lives by finding niche treatments where it can compete and by keeping a steady pipeline of new products coming.
Saved answer · last researched 16 Nov 2026